Published in Muscle Nerve on September 01, 2000
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry (2002) 1.71
Association between functional capacity tests and fractures: an eight-year prospective population-based cohort study. Osteoporos Int (2008) 0.99
Handgrip performance in relation to self-perceived fatigue, physical functioning and circulating IL-6 in elderly persons without inflammation. BMC Geriatr (2007) 0.98
Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry (2003) 0.95
Sarcopenia and its determinants among Iranian elderly (SARIR): study protocol. J Diabetes Metab Disord (2012) 0.87
Serum 25-hydroxyvitamin D concentration and physical function in adult men. Clin Endocrinol (Oxf) (2011) 0.86
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. J Neural Transm (Vienna) (2008) 0.78
Assessment of intensive care unit-acquired weakness in young and old mice: An E. coli septic peritonitis model. Muscle Nerve (2015) 0.75
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A (1997) 4.70
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med (1992) 4.25
Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial. BMJ (1998) 3.90
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet (2004) 3.70
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve (1991) 3.29
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology (1998) 3.13
Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med (2001) 2.94
Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain (2002) 2.89
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 2.84
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev (1992) 2.44
Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology (2010) 2.29
Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry (1998) 2.24
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Recurrent Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry (2008) 2.03
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology (2010) 1.80
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology (2010) 1.80
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology (2010) 1.77
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler (2001) 1.76
Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg (1990) 1.75
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology (1996) 1.74
Cardiac involvement in adults with Pompe disease. J Intern Med (2008) 1.72
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry (2002) 1.71
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry (1998) 1.70
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet (1995) 1.60
Linkage of proximal myotonic myopathy to chromosome 3q. Neurology (1999) 1.60
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol (1996) 1.58
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med (2000) 1.52
Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve (2000) 1.50
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt (2002) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Ptosis as a feature of late-onset glycogenosis type II. Neurology (2006) 1.49
Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg (1997) 1.48
The occurrence of Guillain-Barre syndrome within families. Neurology (2004) 1.48
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol (2012) 1.45
[Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis]. Ned Tijdschr Geneeskd (1993) 1.42
Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. Acta Neurol Scand (2003) 1.40
[Double vision as a symptom of a serious disorder]. Ned Tijdschr Geneeskd (1998) 1.39
Indices from flow-volume curves in relation to cephalometric, ENT- and sleep-O2 saturation variables in snorers with and without obstructive sleep-apnoea. Eur Respir J (1995) 1.39
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation. Neuron (1996) 1.36
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology (2000) 1.36
Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler (2003) 1.34
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34
Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet (1995) 1.33
The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): development and preliminary data. Neuromuscul Disord (2006) 1.33
Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ (2003) 1.32
Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst (2001) 1.32
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res (2001) 1.32
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1993) 1.28
Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology (1999) 1.27
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology (2002) 1.26
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer (1996) 1.24
Incisional hernia after upper abdominal surgery: a randomised controlled trial of midline versus transverse incision. Hernia (2009) 1.24
Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci (1997) 1.22
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol (1996) 1.21
Long-term results of uvulopalatopharyngoplasty for obstructive sleep apnea syndrome. Laryngoscope (2000) 1.20
A prospective randomized trial of high versus low vacuum drainage after axillary dissection for breast cancer. Am J Surg (1997) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology (2004) 1.17
Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol (1983) 1.16
Multivariate logistic analysis of risk factors for stroke in Tilburg, The Netherlands. Am J Epidemiol (1983) 1.15
Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2006) 1.15
Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg (1993) 1.15
Meningeal hyperperfusion visualized by MRI in a patient with visual hallucinations and migraine. Headache (1996) 1.15
Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology (1996) 1.15
Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab (2011) 1.14
Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology (2000) 1.14
Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest (1999) 1.14